Micro-stent is safe and effective after 2-years

Article

A supracilliary micro-stent, when implanted in conjunction with cataract surgery, substantially reduces intraocular pressure (IOP) with minimal complications in patients with open-angle glaucoma, according to researchers in Germany and the US.

A supracilliary micro-stent (CyPass, Transcend Medical, Menlo Park, California, USA), when implanted in conjunction with cataract surgery, substantially reduces intraocular pressure (IOP) with minimal complications in patients with open-angle glaucoma (OAG), according to researchers in Germany and the US.

The researchers conducted a multicentre, prospective, consecutive case series of 136 eyes in 136 subjects with OAG. All of the eyes required cataract surgery, and underwent a combined phacoemulsification with intraocular lens insertion and implantation of the micro-stent. The researchers examined 24-month postoperative data.

At baseline, the subjects were divided into two cohorts: Cohort 1 (51 patients) had uncontrolled IOP of greater than 21 mmHg; Cohort 2 (85 patients) had controlled IOP of less than 21 mmHg. All of the patients were receiving glaucoma medications, which were discontinued postoperatively.

Eighty-two patients remained in the study through the 24-month follow up. After 24 months, the mean IOP in Cohort 1 (23 patients) was 15.8 ± 3.8 mmHg (a reduction of 37% ± 19%). The mean IOP decrease from baseline in Cohort 1 was statistically significant (P P = 0.0188) and 12 (P = 0.0356) in Cohort 2.

No sight-threatening adverse events occurred, and there was a statistically significant mean decrease of glaucoma medication use in both cohorts. To read an abstract of the study published in Klinische Monatsblätter für Augenheilkunde, click here.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
© 2025 MJH Life Sciences

All rights reserved.